COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area
Abstract Background Cancer patients have been reported to be at higher risk of COVID-19 complications and deaths. We report the characteristics and outcome of patients diagnosed with COVID-19 during breast cancer treatment at Institut Curie hospitals (ICH, Paris area, France). Methods An IRB-approve...
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-05-01
|
Series: | Breast Cancer Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13058-020-01293-8 |
id |
doaj-3ffdcc67e1c249f98223450d86a4e01c |
---|---|
record_format |
Article |
spelling |
doaj-3ffdcc67e1c249f98223450d86a4e01c2021-04-02T12:33:46ZengBMCBreast Cancer Research1465-542X2020-05-0122111010.1186/s13058-020-01293-8COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris areaPerrine Vuagnat0Maxime Frelaut1Toulsie Ramtohul2Clémence Basse3Sarah Diakite4Aurélien Noret5Audrey Bellesoeur6Vincent Servois7Delphine Hequet8Enora Laas9Youlia Kirova10Luc Cabel11Jean-Yves Pierga12Institut Curie Breast Cancer and COVID GroupLaurence Bozec13Xavier Paoletti14Paul Cottu15François-Clément Bidard16UVSQ, Université Paris-SaclayDepartment of Drug Development and Innovation, Institut CurieDepartment of Radiology, Institut CurieDepartment of Medical Oncology, Institut CurieDepartment of Medical Oncology, Institut CurieDepartment of Medical Oncology, Institut CurieDepartment of Medical Oncology, Institut CurieDepartment of Radiology, Institut CurieDepartment of Surgical Oncology, Institut CurieDepartment of Surgical Oncology, Institut CurieDepartment of Radiation Oncology, Institut CurieDepartment of Medical Oncology, Institut CurieDepartment of Medical Oncology, Institut CurieDepartment of Medical Oncology, Institut CurieUVSQ, Université Paris-SaclayDepartment of Medical Oncology, Institut CurieUVSQ, Université Paris-SaclayAbstract Background Cancer patients have been reported to be at higher risk of COVID-19 complications and deaths. We report the characteristics and outcome of patients diagnosed with COVID-19 during breast cancer treatment at Institut Curie hospitals (ICH, Paris area, France). Methods An IRB-approved prospective registry was set up at ICH on March 13, 2020, for all breast cancer patients with COVID-19 symptoms or radiologic signs. Registered data included patient history, tumor characteristics and treatments, COVID-19 symptoms, radiological features, and outcome. Data extraction was done on April 25, 2020. COVID-19 patients were defined as those with either a positive RNA test or typical, newly appeared lung CT scan abnormalities. Results Among 15,600 patients actively treated for early or metastatic breast cancer during the last 4 months at ICH, 76 patients with suspected COVID-19 infection were included in the registry and followed. Fifty-nine of these patients were diagnosed with COVID-19 based on viral RNA testing (N = 41) or typical radiologic signs: 37/59 (63%) COVID-19 patients were treated for metastatic breast cancer, and 13/59 (22%) of them were taking corticosteroids daily. Common clinical features mostly consisted of fever and/or cough, while ground-glass opacities were the most common radiologic sign at diagnosis. We found no association between prior radiation therapy fields or extent of radiation therapy sequelae and extent of COVID-19 lung lesions. Twenty-eight of these 59 patients (47%) were hospitalized, and 6 (10%) were transferred to an intensive care unit. At the time of analysis, 45/59 (76%) patients were recovering or had been cured, 10/59 (17%) were still followed, and 4/59 (7%) had died from COVID-19. All 4 patients who died had significant non-cancer comorbidities. In univariate analysis, hypertension and age (> 70) were the two factors associated with a higher risk of intensive care unit admission and/or death. Conclusions This prospective registry analysis suggests that the COVID-19 mortality rate in breast cancer patients depends more on comorbidities than prior radiation therapy or current anti-cancer treatment. Special attention must be paid to comorbidities when estimating the risk of severe COVID-19 in breast cancer patients.http://link.springer.com/article/10.1186/s13058-020-01293-8SARS-CoV-2COVID-19Breast cancerOutcomeSurvival |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Perrine Vuagnat Maxime Frelaut Toulsie Ramtohul Clémence Basse Sarah Diakite Aurélien Noret Audrey Bellesoeur Vincent Servois Delphine Hequet Enora Laas Youlia Kirova Luc Cabel Jean-Yves Pierga Institut Curie Breast Cancer and COVID Group Laurence Bozec Xavier Paoletti Paul Cottu François-Clément Bidard |
spellingShingle |
Perrine Vuagnat Maxime Frelaut Toulsie Ramtohul Clémence Basse Sarah Diakite Aurélien Noret Audrey Bellesoeur Vincent Servois Delphine Hequet Enora Laas Youlia Kirova Luc Cabel Jean-Yves Pierga Institut Curie Breast Cancer and COVID Group Laurence Bozec Xavier Paoletti Paul Cottu François-Clément Bidard COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area Breast Cancer Research SARS-CoV-2 COVID-19 Breast cancer Outcome Survival |
author_facet |
Perrine Vuagnat Maxime Frelaut Toulsie Ramtohul Clémence Basse Sarah Diakite Aurélien Noret Audrey Bellesoeur Vincent Servois Delphine Hequet Enora Laas Youlia Kirova Luc Cabel Jean-Yves Pierga Institut Curie Breast Cancer and COVID Group Laurence Bozec Xavier Paoletti Paul Cottu François-Clément Bidard |
author_sort |
Perrine Vuagnat |
title |
COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area |
title_short |
COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area |
title_full |
COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area |
title_fullStr |
COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area |
title_full_unstemmed |
COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area |
title_sort |
covid-19 in breast cancer patients: a cohort at the institut curie hospitals in the paris area |
publisher |
BMC |
series |
Breast Cancer Research |
issn |
1465-542X |
publishDate |
2020-05-01 |
description |
Abstract Background Cancer patients have been reported to be at higher risk of COVID-19 complications and deaths. We report the characteristics and outcome of patients diagnosed with COVID-19 during breast cancer treatment at Institut Curie hospitals (ICH, Paris area, France). Methods An IRB-approved prospective registry was set up at ICH on March 13, 2020, for all breast cancer patients with COVID-19 symptoms or radiologic signs. Registered data included patient history, tumor characteristics and treatments, COVID-19 symptoms, radiological features, and outcome. Data extraction was done on April 25, 2020. COVID-19 patients were defined as those with either a positive RNA test or typical, newly appeared lung CT scan abnormalities. Results Among 15,600 patients actively treated for early or metastatic breast cancer during the last 4 months at ICH, 76 patients with suspected COVID-19 infection were included in the registry and followed. Fifty-nine of these patients were diagnosed with COVID-19 based on viral RNA testing (N = 41) or typical radiologic signs: 37/59 (63%) COVID-19 patients were treated for metastatic breast cancer, and 13/59 (22%) of them were taking corticosteroids daily. Common clinical features mostly consisted of fever and/or cough, while ground-glass opacities were the most common radiologic sign at diagnosis. We found no association between prior radiation therapy fields or extent of radiation therapy sequelae and extent of COVID-19 lung lesions. Twenty-eight of these 59 patients (47%) were hospitalized, and 6 (10%) were transferred to an intensive care unit. At the time of analysis, 45/59 (76%) patients were recovering or had been cured, 10/59 (17%) were still followed, and 4/59 (7%) had died from COVID-19. All 4 patients who died had significant non-cancer comorbidities. In univariate analysis, hypertension and age (> 70) were the two factors associated with a higher risk of intensive care unit admission and/or death. Conclusions This prospective registry analysis suggests that the COVID-19 mortality rate in breast cancer patients depends more on comorbidities than prior radiation therapy or current anti-cancer treatment. Special attention must be paid to comorbidities when estimating the risk of severe COVID-19 in breast cancer patients. |
topic |
SARS-CoV-2 COVID-19 Breast cancer Outcome Survival |
url |
http://link.springer.com/article/10.1186/s13058-020-01293-8 |
work_keys_str_mv |
AT perrinevuagnat covid19inbreastcancerpatientsacohortattheinstitutcuriehospitalsintheparisarea AT maximefrelaut covid19inbreastcancerpatientsacohortattheinstitutcuriehospitalsintheparisarea AT toulsieramtohul covid19inbreastcancerpatientsacohortattheinstitutcuriehospitalsintheparisarea AT clemencebasse covid19inbreastcancerpatientsacohortattheinstitutcuriehospitalsintheparisarea AT sarahdiakite covid19inbreastcancerpatientsacohortattheinstitutcuriehospitalsintheparisarea AT aureliennoret covid19inbreastcancerpatientsacohortattheinstitutcuriehospitalsintheparisarea AT audreybellesoeur covid19inbreastcancerpatientsacohortattheinstitutcuriehospitalsintheparisarea AT vincentservois covid19inbreastcancerpatientsacohortattheinstitutcuriehospitalsintheparisarea AT delphinehequet covid19inbreastcancerpatientsacohortattheinstitutcuriehospitalsintheparisarea AT enoralaas covid19inbreastcancerpatientsacohortattheinstitutcuriehospitalsintheparisarea AT youliakirova covid19inbreastcancerpatientsacohortattheinstitutcuriehospitalsintheparisarea AT luccabel covid19inbreastcancerpatientsacohortattheinstitutcuriehospitalsintheparisarea AT jeanyvespierga covid19inbreastcancerpatientsacohortattheinstitutcuriehospitalsintheparisarea AT institutcuriebreastcancerandcovidgroup covid19inbreastcancerpatientsacohortattheinstitutcuriehospitalsintheparisarea AT laurencebozec covid19inbreastcancerpatientsacohortattheinstitutcuriehospitalsintheparisarea AT xavierpaoletti covid19inbreastcancerpatientsacohortattheinstitutcuriehospitalsintheparisarea AT paulcottu covid19inbreastcancerpatientsacohortattheinstitutcuriehospitalsintheparisarea AT francoisclementbidard covid19inbreastcancerpatientsacohortattheinstitutcuriehospitalsintheparisarea |
_version_ |
1721568449678802944 |